Teprenone

HSP70 Inducer

Product Specifications

Background

Teprenone can induce expression of HSP70, HSPB8, and HSPB1. Induction of HSP70 expression is protective against the development of various diseases, such as inflammatory bowel disease, hypoxic/ischemic brain injury and spinal and bulbar muscular atrophy (cytoprotective and anti-inflammatory effects) (1, 2). Reports indicate that Teprenone protects against NSAID-induced gastric and intestinal lesions by induction of HSP70 expression (2). Other studies have shown that it induces expression of HSPB8 and HSPB1 and reduces the formation of amyloid oligomers as well as insoluble aggregates in HSPB5 R120G TG mice (3, 4).

Product Name Alternative

Geranylgeranylacetone, GGA, 6,10,14,18-Tetramethyl-5,9,13,17-nonadecatetraen-2-one

UNSPSC

41116105

Source

Synthetic

Purity

>95% (GC)

Weight

0.05

Format

Colorless Oil

Solubility

Soluble in DMSO (30 mg/ml)

Molecular Formula

C23H38O

Molecular Weight

330.6

Precautions

Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.

References & Citations

1. Kobayashi T., Ohta Y., Yoshino J and Nakazawa S. (2001) Pharmacol Res. 43(1): 23-30. 2. Sambroski P., Grzymislawski M. (2015) Adv Clin Med. 24(3): 525-530. 3. Marunouchi T., Inomata S., Sanbe A., Takagi N., Tanonaka K. (2014) Eur J Pharmacol. 730: 1401-47. 4. Sanbe A., et al. (2009) PLoS One. 4(4): e5351.